Krystal Biotech, Inc. (NASDAQ:KRYS) Given Consensus Recommendation of “Buy” by Analysts

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have been given a consensus rating of “Buy” by the eight analysts that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $220.00.

KRYS has been the topic of several recent analyst reports. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 target price on shares of Krystal Biotech in a research report on Thursday, February 20th. Citigroup lifted their price objective on Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research note on Thursday, February 20th. Jefferies Financial Group started coverage on shares of Krystal Biotech in a research report on Wednesday, March 5th. They issued a “buy” rating and a $245.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a report on Friday, February 28th. Finally, Chardan Capital upped their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a report on Thursday, February 20th.

Insider Activity at Krystal Biotech

In other news, CAO Kathryn Romano sold 750 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the sale, the chief accounting officer now owns 12,604 shares in the company, valued at $2,208,472.88. This represents a 5.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the sale, the insider now directly owns 1,463,711 shares of the company’s stock, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their position. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Krystal Biotech

A number of large investors have recently made changes to their positions in KRYS. Wellington Management Group LLP lifted its stake in shares of Krystal Biotech by 15.1% in the 3rd quarter. Wellington Management Group LLP now owns 12,680 shares of the company’s stock worth $2,308,000 after purchasing an additional 1,660 shares during the period. Geode Capital Management LLC grew its holdings in Krystal Biotech by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock valued at $107,714,000 after buying an additional 11,411 shares in the last quarter. Teachers Retirement System of The State of Kentucky raised its stake in Krystal Biotech by 198.2% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 9,010 shares of the company’s stock valued at $1,640,000 after purchasing an additional 5,989 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new position in shares of Krystal Biotech in the 3rd quarter worth approximately $40,000. Finally, Franklin Resources Inc. increased its position in Krystal Biotech by 34.2% during the third quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock valued at $43,774,000 after acquiring an additional 62,178 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Trading Up 0.1 %

KRYS opened at $169.13 on Friday. Krystal Biotech has a 1-year low of $141.72 and a 1-year high of $219.34. The company has a fifty day moving average price of $174.25 and a two-hundred day moving average price of $172.13. The company has a market cap of $4.89 billion, a P/E ratio of 56.57 and a beta of 0.75.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. The business had revenue of $91.10 million during the quarter, compared to the consensus estimate of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The company’s quarterly revenue was up 116.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.30 EPS. On average, research analysts forecast that Krystal Biotech will post 6.14 EPS for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).